Results of bioequivalence studies on the drugs gestodene+ethinylestradiol and drospirenone+ethinylestradiol in healthy volunteers

Dumanovskaya M.R.

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia
The paper presents the results of three bioequivalence studies on drugs PlanyGens gesto 20 (gestoden 0.075 mg + ethinylestradiol 0.02 mg), PlanyGens gesto 30 (gestoden 0.075 mg + ethinylestradiol 0.03 mg), PlanyGens drospi (drospirenone 3 mg + ethinylestradiol 0.03 mg) produced by “Pharmasyntez-Tyumen” LLC, Russia and relevant original (reference) drugs Logest (Bayer Pharma AG, Germany), Femoden (Bayer Pharma AG, Germany) and Yarina (Bayer Pharma AG, Germany). During the bioequivalence studies, the pharmacokinetic parameters of gestodene+ethinylestradiol and drospirenone+ethinylestradiol were determined in the blood plasma of healthy volunteers after a single oral intake of the compared drugs on an empty stomach according to an open randomized cross-scheme in two stages. The concentration of gestodene+ethinylestradiol and drospirenone+ethinylestradiol in blood plasma was analyzed with the help of bioanalytic method using highly sensitive and selective high-performance liquid chromatography with tandem mass spectrometric detection. The following pharmacological parameters were calculated for the analyzed drugs: AUC0-72, AUC0-∞, Cmax, Tmax, T½, kel, f’, f’’, Cmax/AUC, MRT. The 90% confidence intervals for the ratio of the geometric mean AUC0-t and Cmax parameters lay in the range of 80.00–125.00% in bioequivalence studies of drugs.
Conclusion: The findings led to the conclusions about the bioequivalence of the test and reference drugs gestodene+ethinylestradiol and drospirenone+ethinylestradiol. The safety profiles of the compared drugs were comparable.

Conflicts of interest: The authors declare no possible conflicts of interest.
Funding: The study was conducted without sponsorship.
Acknowledgements: The author expresses gratitude to Irina A. Proskurina, PhD, Head of the Department No. 2 in the Effectiveness and Safety of Drugs, Scientific Centre for Expert Evaluation of Medicinal Products, for assistance in preparing the article.
For citation: Dumanovskaya M.R. Results of bioequivalence studies on the drugs gestodene+ethinylestradiol and drospirenone+ethinylestradiol in healthy volunteers.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2023; (8): 192-202 (in Russian)


pharmacokinetic parameters
PlanyGens gesto 20
PlanyGens gesto 30
PlanyGens drospi


  1. Bearak J., Popinchalk A., Ganatra B., Moller A.-B., Tunçalp Ö., Beavin C. et al. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990–2019. Lancet Glob. Health. 2020; 8(9): e1152-61.
  2. Ganatra B., Gerdts C., Rossier C., Johnson B.R. Jr, Tunçalp Ö., Assifi A. et al. Global, regional, and subregional classification of abortions by safety, 2010-14: estimates from a Bayesian hierarchical model. Lancet. 2017; 390(10110):2372-81.
  3. Say L., Chou D., Gemmill A., Tunçalp Ö., Moller A.B., Daniels J. et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob. Health. 2014; 2(6): e323-33.
  4. Singh S., Maddow-Zimet I. Facility-based treatment for medical complications resulting from unsafe pregnancy termination in the developing world, 2012: a review of evidence from 26 countries. BJOG. 2016; 123(9): 1489-98.
  6. Christin-Maitre S. Worldwide contraception. Med. Sci. (Paris). 2022; 38(5): 457-63. (in French).
  7. de Molina-Fernandez M.I., Reyes-Martí L., De la Flor-López M., Aguarón-García M.J., Roca-Biosca A., Rubio-Rico L. et al. Medication adherence and contraceptive counseling. Healthcare (Basel). 2023;11(9): 1304.https://dx.doi.org10.3390/healthcare11091304.
  8. Adarve-Hidalgo E., Falguera G., Seguranyes G. Adherencia y cumplimiento del método anticonceptivo hormonal oral. Matronas Profesión. 2016; 17(1): 28-34.
  9. Accessed 17.07.23.
  10. Practice Committee of the American Society for Reproductive Medicine. Electronic address:; Practice Committee of the American Society for Reproductive Medicine. Combined hormonal contraception and the risk of venous thromboembolism: a guideline.
  11. Vinciguerra M., Cascardi E., Lamanna B., Marrone M., Pititto F., Macorano E. et al. A multi-institutional informed consent proposal as a prevention tool for combined oral contraceptive intake and thrombotic risk. J. Pers. Med. 2023; 13(4): 584.
  12. Martinelli I., Maino A., Abbattista M., Bucciarelli P., Passamonti S.M., Artoni A. et al. Duration of oral contraceptive use and the risk of venous thromboembolism. A case-control study. Thromb. Res. 2016; 141: 153-7.
  13. LaVasseur C., Neukam S., Kartika T., Samuelson Bannow B, Shatzel J, DeLoughery T.G. Hormonal therapies and venous thrombosis: Considerations for prevention and management. Res. Pract. Thromb. Haemost. 2022; 6(6): e12763.
  14. Rosano G.M.C., Rodriguez-Martinez M.A., Spoletini I., Regidor P.A. Obesity and contraceptive use: impact on cardiovascular risk. ESC Heart Fail. 2022; 9(6): 3761-7.
  15. Schindler A.E. Non-contraceptive benefits of oral hormonal contraceptives. Int. J. Endocrinol. Metab. 2013; 11(1): 41-7.
  16. Michels K.A., Pfeiffer R.M., Brinton L.A., Trabert B. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA Oncol. 2018; 4(4): 516-21.
  17. Black A., Guilbert E., Costescu D., Dunn S., Fisher W., Kives S. et al. No. 329-canadian contraception consensus part 4 of 4 chapter 9: combined hormonal contraception. J. Obstet. Gynaecol. Can. 2017; 39(4): 229-68.e5.
  18. Dellino M., Silvestris E., Loizzi V., Paradiso A., Loiacono R., Minoia C. et al. Germinal ovarian tumors in reproductive age women: Fertility-sparing and outcome. Medicine (Baltimore). 2020 ;99(39): e22146.
  19. van Hylckama Vlieg A., Helmerhorst F.M., Vandenbroucke J.P., Doggen C.J., Rosendaal F.R. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009; 339: b2921.
  20. Li L., Yang X., Tran D., Seo S.K., Lu Y. Combined oral contraceptives as victims of drug interactions. Drug Metab. Dispos. 2023; 51(6): 718-32.
  21. Журавлева М.В., Сереброва С.Ю., Пономаренко Т.М., Городецкая Г.И. Гормональная контрацепция: история и инновации. Проблемы репродукции. 2017; 23(4): 37‑43. [Zhuravleva M.V., Serebrova S.Yu., Ponomarenko T.M., Gorodetskaya G.I. Hormonal contraception: history and innovations. Russian Journal of Human Reproduction. 2017; 23(4): 37‑43.(in Russian)].
  22. Potter J., Santelli J.S. Adolescent contraception: review and guidance for pediatric clinicians. Minerva Pediatr. 2015; 67(1): 33-45.
  23. Dmitrovic R., Kunselman A.R., Legro R.S. Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstet. Gynecol. 2012; 119(6): 1143-50.
  24. Сметник А.А. Контрацепция с дроспиреноном: влияние на массу тела и некоторые показатели метаболизма липидов. Медицинский совет. 2016; 12: 95-7. [Smetnik A.A. Contraception with drospirenone: effect on the body weight and some lipid metabolism indicators. Medical Council. 2016; (12): 95-7. (in Russian)].
  25. Миронов А.Н., Кукес В.Г., Петров В.И., Кузнецов А.Л., Горячев Д.В., Ниязов Р.Р., Прокофьев А.Б., Недогода С.В., Фролов М.Ю., Шнайдер А. Изучение биоэквивалентности воспроизведенных лекарственных средств. В кн.: Руководство по экспертизе лекарственных средств. т. 1. М.: Гриф и К; 2014: 174-216. [Mironov A.N., Kukes V.G., Petrov V.I., Kuznetsov A.L., Goryachev D.V., Niyazov R.R., Prokofiev A.B., Nedogoda S.V., Frolov M.Yu., Schneider A. Study of bioequivalence of reproduced drugs. In: Guidelines for the examination of medicinal products. vol. 1. Moscow: Grif and K; 2014: 174-216. (in Russian)].
  26. Министерство здравоохранения и социального развития Российской Федерации, Федеральная служба по надзору в сфере здравоохранения и социального развития, Федеральное государственное учреждение «Научный центр экспертизы средств медицинского применения». Оценка биоэквивалентности лекарственных средств. Методические указания. М.; 2008. [Ministry of Health and Social Development of the Russian Federation, Federal Service for Surveillance in Healthcare and Social Development, Federal State Institution "Scientific Center for Expertise of Medicinal Products". Evaluation of bioequivalence of drugs. Methodical instructions. Moscow; 2008. (in Russian)].
  27. Правила проведения исследований биоэквивалентности лекарственных препаратов в рамках Евразийского экономического союза (Решение Совета Евразийской экономической комиссии от 3 ноября 2016 г. No 85). [Rules for conducting bioequivalence studies of medicinal products within the framework of the Eurasian Economic Union (Decision of the Council of the Eurasian Economic Commission of November 3, 2016 No. 85).(in Russian)].

Received 21.07.2023

Accepted 16.08.2023

About the Authors

Madina R. Dumanovskaya, PhD, Researcher at the Department of Gynecological Endocrinology, Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia,,, 117997, Russia, Moscow, Ac. Oparin str., 4.

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.